Santen Pharmaceutical Co., Ltd.: all 94 studies

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control GroupRecruitingNCT07235592
• A Study in Chinese Patients With Acquired BlepharoptosisRecruitingNCT06683651Phase 3
• LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.RecruitingNCT06514612Phase 3
• Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With PresbyopiaCompletedNCT05665387Phase 2Results posted
• A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedNCT05376176Phase 2Results posted
• Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT04742283Phase 2Results posted
• PRESERFLO® MicroShunt Extension StudyCompletedNCT04333433Results posted
• 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)CompletedNCT04144413Phase 3Results posted
• A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT04133311Phase 3Results posted
• Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6CompletedNCT03858894Phase 2Results posted
• LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the EyeTerminatedNCT03711929Phase 3Results posted
• DE-117 Spectrum 5 StudyCompletedNCT03697811Phase 3Results posted
• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 StudyCompletedNCT03691662Phase 3Results posted
• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 StudyCompletedNCT03691649Phase 3Results posted
• Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe KeratitisCompletedNCT03237936Phase 4Results posted
• A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel StudyCompletedNCT03216902Phase 2Results posted
• Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration SubjectsCompletedNCT03211234Phase 2Results posted
• A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHTCompletedNCT02981446Phase 3Results posted
• A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular DegenerationCompletedNCT02555306Phase 1/2Results posted
• A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development ProgramCompletedNCT02251938Phase 3Results posted
• Post Market Study of the InnFocus MicroShuntCompletedNCT02177123Not applicableResults posted
• Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial AsthmaCompletedNCT02097537Phase 3Results posted
• InnFocus MicroShunt Versus Trabeculectomy StudyCompletedNCT01881425Not applicableResults posted
• Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal KeratoconjunctivitisCompletedNCT01751126Phase 3Results posted
• Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage ImplantCompletedNCT01563237Not applicableResults posted
• A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedNCT01363713Phase 3Results posted
• Study of DE-114 Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedNCT01363700Phase 3Results posted
• Study Assessing Double-masked Uveitis TreatmentCompletedNCT01358266Phase 3Results posted
• DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01343082Phase 3Results posted
• DE-111 Against Timolol Ophthalmic Solution 0.5%CompletedNCT01342094Phase 3Results posted
• DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%CompletedNCT01342081Phase 3Results posted
• Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01240382Phase 3Results posted
• Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01189032Phase 2Results posted
• Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved FormulationCompletedNCT00918346Phase 3Results posted
• Clinical Study of the Safety and Performance of the Miami InnFocus Drainage Implant to Relieve Glaucoma SymptomsCompletedNCT00772330Not applicableResults posted
• Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)CompletedNCT00328653Phase 2/3Results posted
• Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.CompletedNCT06912802
• A Pharmacokinetics (PK) Study in Healthy AdultsCompletedNCT06911216Early Phase 1
• A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaActive, not recruitingNCT06666855Phase 3
• Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males VolunteersCompletedNCT05905653Phase 1
• A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular HypertensionCompletedNCT05503901Phase 3
• A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT05495061Phase 3
• Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag IsopropylStatus unknownNCT05279716Phase 4
• Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World SettingCompletedNCT04828057
• Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)CompletedNCT04737928Not applicable
• 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisCompletedNCT04701086Not applicable
• 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisActive, not recruitingNCT04685109Not applicable
• Prevalence of Ocular Surface Disease in Malaysian Glaucoma PatientsStatus unknownNCT04609345
• A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular HypertensionCompletedNCT03822559Phase 3
• A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)CompletedNCT03329638Phase 2
• Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye DiseaseCompletedNCT03216096Phase 1
• A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract SurgeryCompletedNCT02888210Phase 3
• A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI StudyCompletedNCT02822742Phase 3
• A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE StudyCompletedNCT02822729Phase 3
• A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -CompletedNCT02650063Phase 1
• A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-CompletedNCT02623738Phase 2/3
• Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract SurgeryCompletedNCT02573610Phase 3
• A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular DegenerationCompletedNCT02401945Phase 2
• Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT02179008Phase 2
• A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular HypertensionCompletedNCT02102750Phase 1
• A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular DegenerationCompletedNCT02022501Phase 1/2
• A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren SyndromeCompletedNCT02011776
• Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT01868126Phase 2
• A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTCompletedNCT01654484Phase 1/2
• Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)CompletedNCT01512901Phase 2/3
• A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedNCT01468168Phase 2
• Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye DropsCompletedNCT01434888Phase 1
• Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)CompletedNCT01411254Phase 2/3
• Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant AdministrationsCompletedNCT01306461Phase 3
• Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against MonotherapiesCompletedNCT01292460Phase 3
• Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01279083Phase 1/2
• Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface DiseaseCompletedNCT01254370Phase 2
• Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye DiseaseCompletedNCT01239069Phase 2
• Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedNCT01118754Phase 1/2
• Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01101984Not applicable
• Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye DropsCompletedNCT01087671Phase 3
• Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial DefectCompletedNCT00988494Phase 2
• Interaction Study of Timolol Eye Drops and Paroxetine CapsulesCompletedNCT00879099Phase 1
• Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular HypertensionCompletedNCT00868894Phase 1/2
• A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) ModelCompletedNCT00814944Phase 2
• Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye SyndromeCompletedNCT00814515Phase 3
• Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular DegenerationTerminatedNCT00766337Phase 2
• Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant SurgeryTerminatedNCT00764582Phase 4
• NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry EyeCompletedNCT00739349Phase 2
• Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular DegenerationTerminatedNCT00712491Phase 1/2
• Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active ComparatorsCompletedNCT00703313Phase 4
• Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic RetinopathyCompletedNCT00665106Phase 1
• Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00657579Phase 2
• Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular EdemaCompletedNCT00656643Phase 2
• To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00656240Phase 2
• Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular HypertensionCompletedNCT00650338Phase 2
• Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active ComparatorCompletedNCT00630019Phase 4
• Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye DropsCompletedNCT00596791Phase 3
• Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic RetinopathyCompletedNCT00401115Phase 1

← Santen Pharmaceutical Co., Ltd. overview and focus areas